Boston Scientific Co. (NYSE:BSX) Holdings Lifted by Sunbelt Securities Inc.

Sunbelt Securities Inc. boosted its holdings in Boston Scientific Co. (NYSE:BSX) by 16.6% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,414 shares of the medical equipment provider’s stock after purchasing an additional 201 shares during the quarter. Sunbelt Securities Inc.’s holdings in Boston Scientific were worth $118,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. OFI Invest Asset Management bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $36,000. Western Wealth Management LLC grew its position in Boston Scientific by 5.3% in the second quarter. Western Wealth Management LLC now owns 18,626 shares of the medical equipment provider’s stock worth $1,434,000 after buying an additional 941 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Boston Scientific by 8.7% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 83,953 shares of the medical equipment provider’s stock worth $6,465,000 after buying an additional 6,737 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Boston Scientific by 15.6% in the second quarter. Nisa Investment Advisors LLC now owns 372,867 shares of the medical equipment provider’s stock valued at $28,714,000 after buying an additional 50,397 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its position in shares of Boston Scientific by 14.5% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 611,693 shares of the medical equipment provider’s stock valued at $47,106,000 after acquiring an additional 77,677 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now directly owns 1,572,096 shares in the company, valued at $133,046,484.48. This represents a 9.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total value of $585,594.38. Following the transaction, the executive vice president now directly owns 34,748 shares of the company’s stock, valued at $2,913,967.28. This represents a 16.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 328,157 shares of company stock worth $27,957,676 over the last 90 days. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Morgan Stanley boosted their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Mizuho raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Truist Financial lifted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Royal Bank of Canada upped their price target on shares of Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.43.

Boston Scientific Stock Down 0.3 %

BSX stock opened at $90.11 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a market cap of $132.81 billion, a PE ratio of 74.47, a PEG ratio of 2.67 and a beta of 0.80. Boston Scientific Co. has a 1 year low of $54.95 and a 1 year high of $91.93. The company has a fifty day simple moving average of $87.98 and a 200 day simple moving average of $81.82.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the prior year, the company posted $0.50 EPS. The firm’s revenue was up 19.3% on a year-over-year basis. Sell-side analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.